// #gcp

Novo Nordisk Discloses Breach of Clinical Trial Participant Data — Ozempic and GLP-1 Research Records Exposed

Danish pharmaceutical giant Novo Nordisk has disclosed a cybersecurity incident in which attackers gained unauthorised access to IT systems holding personal data of clinical trial participants, including individuals enrolled in GLP-1 receptor agonist trials for Ozempic and Wegovy. The breach raises significant regulatory concerns under EU clinical trial data protection requirements and the ICH GCP framework governing trial participant data handling.